Cargando…

Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients

Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use....

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Karla R., Aikawa, Nádia E., Saad, Carla Gonçalves, Moraes, Júlio C. B., Medeiros, Ana C., Mota, Licia Maria H., Silva, Clovis A. A., Bonfá, Eloísa, Carvalho, Jozélio F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143445/
https://www.ncbi.nlm.nih.gov/pubmed/21804855
http://dx.doi.org/10.1155/2011/352686
_version_ 1782208912837050368
author Castro, Karla R.
Aikawa, Nádia E.
Saad, Carla Gonçalves
Moraes, Júlio C. B.
Medeiros, Ana C.
Mota, Licia Maria H.
Silva, Clovis A. A.
Bonfá, Eloísa
Carvalho, Jozélio F.
author_facet Castro, Karla R.
Aikawa, Nádia E.
Saad, Carla Gonçalves
Moraes, Júlio C. B.
Medeiros, Ana C.
Mota, Licia Maria H.
Silva, Clovis A. A.
Bonfá, Eloísa
Carvalho, Jozélio F.
author_sort Castro, Karla R.
collection PubMed
description Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8 ± 49.7 versus 140.1 ± 64.1 mg/dL, P = 0.028) and VLDL-c (23.6 ± 10.5 versus 28.4 ± 13.7 mg/dL, P = 0.019) levels. In contrast, there were no differences in the mean TC (P = 0.28), LDL-c (P = 0.42), and HDL-c (P = 0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P > 0.05). Positive correlations were found between VLDL-c and CRP (r = 0.647, P = 0.009) and between triglycerides and CRP (r = 0.604, P = 0.017) levels at 3M. ESR reduction was observed after 3M (P = 0.04). Mean prednisone dose remained stable at beginning and at 3M (P = 0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months.
format Online
Article
Text
id pubmed-3143445
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31434452011-07-29 Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients Castro, Karla R. Aikawa, Nádia E. Saad, Carla Gonçalves Moraes, Júlio C. B. Medeiros, Ana C. Mota, Licia Maria H. Silva, Clovis A. A. Bonfá, Eloísa Carvalho, Jozélio F. Clin Dev Immunol Research Article Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8 ± 49.7 versus 140.1 ± 64.1 mg/dL, P = 0.028) and VLDL-c (23.6 ± 10.5 versus 28.4 ± 13.7 mg/dL, P = 0.019) levels. In contrast, there were no differences in the mean TC (P = 0.28), LDL-c (P = 0.42), and HDL-c (P = 0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P > 0.05). Positive correlations were found between VLDL-c and CRP (r = 0.647, P = 0.009) and between triglycerides and CRP (r = 0.604, P = 0.017) levels at 3M. ESR reduction was observed after 3M (P = 0.04). Mean prednisone dose remained stable at beginning and at 3M (P = 0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months. Hindawi Publishing Corporation 2011 2011-07-24 /pmc/articles/PMC3143445/ /pubmed/21804855 http://dx.doi.org/10.1155/2011/352686 Text en Copyright © 2011 Karla R. Castro et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Castro, Karla R.
Aikawa, Nádia E.
Saad, Carla Gonçalves
Moraes, Júlio C. B.
Medeiros, Ana C.
Mota, Licia Maria H.
Silva, Clovis A. A.
Bonfá, Eloísa
Carvalho, Jozélio F.
Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
title Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
title_full Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
title_fullStr Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
title_full_unstemmed Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
title_short Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
title_sort infliximab induces increase in triglyceride levels in psoriatic arthritis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143445/
https://www.ncbi.nlm.nih.gov/pubmed/21804855
http://dx.doi.org/10.1155/2011/352686
work_keys_str_mv AT castrokarlar infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients
AT aikawanadiae infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients
AT saadcarlagoncalves infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients
AT moraesjuliocb infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients
AT medeirosanac infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients
AT motaliciamariah infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients
AT silvaclovisaa infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients
AT bonfaeloisa infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients
AT carvalhojozeliof infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients